Skip to main navigation

Skip to content

Side Menu

About Us
Our Platform
Our Programs
Patients and Physicians
Inside Seres
Open Positions
Investors and News
Contact Us

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

Sep 08, 2022

Seres Therapeutics to Present at World Anti-Microbial Resistance Congress

Sep 07, 2022

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Aug 04, 2022

Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

Aug 03, 2022

Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Jul 28, 2022

Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022

Jun 30, 2022

Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock

Jun 07, 2022

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Jun 01, 2022

Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2022

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

May 10, 2022

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2022 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook